These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 3382761)

  • 1. Relevance of cell kinetics to hormonal response of receptor-positive advanced breast cancer.
    Paradiso A; Lorusso V; Tommasi S; Schittulli F; Maiello E; De Lena M
    Breast Cancer Res Treat; 1988 Apr; 11(1):31-6. PubMed ID: 3382761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor-proliferative activity, progesterone receptor status, estrogen receptor level, and clinical outcome of estrogen receptor-positive advanced breast cancer.
    Paradiso A; Tommasi S; Mangia A; Lorusso V; Simone G; De Lena M
    Cancer Res; 1990 May; 50(10):2958-62. PubMed ID: 2334898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study.
    Ravdin PM; Green S; Dorr TM; McGuire WL; Fabian C; Pugh RP; Carter RD; Rivkin SE; Borst JR; Belt RJ
    J Clin Oncol; 1992 Aug; 10(8):1284-91. PubMed ID: 1634918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progesterone receptor positivity is a predictor of long-term benefit from adjuvant tamoxifen treatment of estrogen receptor positive breast cancer.
    Nordenskjöld A; Fohlin H; Fornander T; Löfdahl B; Skoog L; Stål O
    Breast Cancer Res Treat; 2016 Nov; 160(2):313-322. PubMed ID: 27722840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status.
    Dowsett M; Houghton J; Iden C; Salter J; Farndon J; A'Hern R; Sainsbury R; Baum M
    Ann Oncol; 2006 May; 17(5):818-26. PubMed ID: 16497822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pattern of distribution of cells positive for estrogen receptor alpha and progesterone receptor in relation to proliferating cells in the mammary gland.
    Russo J; Ao X; Grill C; Russo IH
    Breast Cancer Res Treat; 1999 Feb; 53(3):217-27. PubMed ID: 10369068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cell kinetics as a predictive factor in node-positive breast cancer treated with adjuvant hormone therapy.
    Silvestrini R; Daidone MG; Mastore M; Di Fronzo G; Coradini D; Boracchi P; Squicciarini P; Salvadori B; Veronesi U
    J Clin Oncol; 1993 Jun; 11(6):1150-5. PubMed ID: 8501501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunohistochemical evaluation of hormone receptor status for predicting response to endocrine therapy in metastatic breast cancer.
    Yamashita H; Yando Y; Nishio M; Zhang Z; Hamaguchi M; Mita K; Kobayashi S; Fujii Y; Iwase H
    Breast Cancer; 2006; 13(1):74-83. PubMed ID: 16518065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98.
    Viale G; Regan MM; Maiorano E; Mastropasqua MG; Dell'Orto P; Rasmussen BB; Raffoul J; Neven P; Orosz Z; Braye S; Ohlschlegel C; Thürlimann B; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS
    J Clin Oncol; 2007 Sep; 25(25):3846-52. PubMed ID: 17679725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. pS2 expression and response to hormonal therapy in patients with advanced breast cancer.
    Schwartz LH; Koerner FC; Edgerton SM; Sawicka JM; Rio MC; Bellocq JP; Chambon P; Thor AD
    Cancer Res; 1991 Jan; 51(2):624-8. PubMed ID: 1985778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative estrogen and progesterone receptor levels related to progression-free interval in advanced breast cancer patients treated with megestrol acetate or tamoxifen.
    Bonomi P; Gale M; Von Roenn J; Anderson K; Johnson P; Wolter J; Economou S
    Semin Oncol; 1988 Apr; 15(2 Suppl 1):26-33. PubMed ID: 3368797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Measurement of steroid hormone receptors in breast cancer patients on tamoxifen.
    Encarnación CA; Ciocca DR; McGuire WL; Clark GM; Fuqua SA; Osborne CK
    Breast Cancer Res Treat; 1993; 26(3):237-46. PubMed ID: 8251648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Premorbid body weight and its relations to primary tumour diameter in breast cancer patients; its dependence on estrogen and progesteron receptor status.
    Maehle BO; Tretli S; Skjaerven R; Thorsen T
    Breast Cancer Res Treat; 2001 Jul; 68(2):159-69. PubMed ID: 11688519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer.
    Henriksen KL; Rasmussen BB; Lykkesfeldt AE; Møller S; Ejlertsen B; Mouridsen HT
    Acta Oncol; 2009; 48(4):522-31. PubMed ID: 19173092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Results of two or five years of adjuvant tamoxifen correlated to steroid receptor and S-phase levels. South Sweden Breast Cancer Group, and South-East Sweden Breast Cancer Group.
    Fernö M; Stål O; Baldetorp B; Hatschek T; Källström AC; Malmström P; Nordenskjöld B; Rydën S
    Breast Cancer Res Treat; 2000 Jan; 59(1):69-76. PubMed ID: 10752681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer.
    Foekens JA; Look MP; Peters HA; van Putten WL; Portengen H; Klijn JG
    J Natl Cancer Inst; 1995 May; 87(10):751-6. PubMed ID: 7563153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype.
    Rakha EA; El-Sayed ME; Green AR; Paish EC; Powe DG; Gee J; Nicholson RI; Lee AH; Robertson JF; Ellis IO
    J Clin Oncol; 2007 Oct; 25(30):4772-8. PubMed ID: 17876012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study.
    Elledge RM; Green S; Pugh R; Allred DC; Clark GM; Hill J; Ravdin P; Martino S; Osborne CK
    Int J Cancer; 2000 Mar; 89(2):111-7. PubMed ID: 10754487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Steroid hormone receptors and clinical usefulness in human breast cancer.
    Nomura Y; Yamagata J; Takenaka K; Tashiro H
    Cancer; 1980 Dec; 46(12 Suppl):2880-3. PubMed ID: 7448732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17.
    Goss PE; Ingle JN; Martino S; Robert NJ; Muss HB; Piccart MJ; Castiglione M; Tu D; Shepherd LE; Pritchard KI; Livingston RB; Davidson NE; Norton L; Perez EA; Abrams JS; Cameron DA; Palmer MJ; Pater JL;
    J Clin Oncol; 2007 May; 25(15):2006-11. PubMed ID: 17452676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.